Hot Flash News and Research

RSS

Hot Flash is a sudden, temporary onset of body warmth, flushing, and sweating (often associated with menopause).

FDA approves FASLODEX 500mg dose for metastatic breast cancer in postmenopausal women

AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of FASLODEX® (fulvestrant) Injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

13 Sep 2010

Study finds non-hormonal therapies can relieve hot flashes in women with breast cancer

Many women enduring hot flashes experience the heat, sweat and reddened upper body as an uncomfortable inconvenience. However, hot flashes can greatly diminish a woman's quality of life, disrupting sleep at night or causing embarrassment as she goes about her daily business. Many women enduring hot flashes experience the heat, sweat and reddened upper body as an uncomfortable inconvenience. However, hot flashes can greatly diminish a woman's quality of life, disrupting sleep at night or causing embarrassment as she goes about her daily business.

8 Sep 2010

Depomed announces SPA agreement with FDA for Serada Phase 3 trial for menopausal hot flashes

Depomed, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment on the design and analysis of Breeze 3, a Phase 3 trial evaluating Serada® (extended release gabapentin tablets) for menopausal hot flashes.

11 Aug 2010

Weight loss related to fewer hot flashes in menopausal women: study

Hot flashes are an uncomfortable and distressing part of menopause that many women go through. Hot flashes also known as hot flushes are usually sudden sweatiness and redness in the face that can remain for four or five years into menopause. Now researchers have shown that losing weight may help reduce these symptoms.

13 Jul 2010

Data shows potential health benefits of S-equol in relieving menopausal symptoms

The findings of a scientific conference examining the growing body of research and potential health benefits of S-equol were published this month in the Journal of Nutrition. Manuscripts based on presentations made at the conference, which was organized by the Life Sciences Research Office, reveal data that S-equol is a safe, natural and effective solution to providing relief of menopausal symptoms such as hot flashes and muscle discomfort.

9 Jul 2010

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from the Tulip PETAL Study (703 Study), its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

10 Dec 2009

Depomed announces results from BREEZE 1 and 2 Phase 3 clinical trials of Serada

Depomed, Inc. announced today top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an investigational non-hormonal extended release formulation of gabapentin for the treatment of menopausal hot flashes.

12 Oct 2009

New soy germ-based ingredient improves menopausal symptoms

SE5-OH containing Natural S-equol, a novel soy germ-based ingredient in a supplement, improved menopausal symptoms, including significantly reducing hot flash frequency by nearly 59 percent, according to a peer-reviewed study in Japanese women.

9 Oct 2009

Botanicals do not have an effect on hot flashes or on cognitive function in menopausal women

Two studies conducted by researchers at the University of Illinois at Chicago and Northwestern University have found that commonly used botanicals do not have an effect on hot flashes or on cognitive function in menopausal women.

6 Aug 2009

Many low-income women breast cancer patients skipping hormonal therapy, lowering their survival rates

Many low-income women are failing to take the hormonal therapy prescribed as part of their breast cancer treatment, possibly lowering their survival rates, according to a study led by a researcher in the Duke Comprehensive Cancer Center.

18 May 2009

Pregabalin shows potential as treatment for hot flashes

A pill used for nerve pain offers women relief from hot flashes, Mayo Clinic researchers report at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).

17 May 2009

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

Ferring Pharmaceuticals has announced the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer.

27 Apr 2009

Lilly granted preliminary injunction to prevent launch of generic Raloxifene

Eli Lilly and Company has announced that the U.S. District Court for the Southern District of Indiana today issued a preliminary injunction to prevent the launch of a generic version of Lilly's medicine Evista (raloxifene HCl tablets) by Teva Pharmaceuticals until the Court renders its final ruling.

22 Apr 2009

Rockefeller University Hospital opens new Sleep Research Center

A good night's sleep is good for your health, but the details have long been sketchy.

20 Apr 2009

Panic attacks immediately following traumatic events do not trigger or predict PTSD in the long-term

New Geisinger-lead research dispels a recent notion in psychiatry that if a person experiences a panic attack during a traumatic event that they will likely suffer from post-traumatic stress disorder (PTSD) in the future.

8 Apr 2009

Bionovo announces publication of positive phase 2 trial results for Menerba

Bionovo, Inc. has announced the online publication of a peer-reviewed article in the journal, Menopause, reporting Menerba(TM) (formerly MF101) is well tolerated, safe and effective for the treatment of vasomotor symptoms (hot flashes and night sweats) associated with menopause.

2 Apr 2009

Radius starts Ppase 2a trial of RAD1901 in menopausal hot flashes

Radius Health ("Radius") announced today that the first patient has been dosed in the company's proof-of-concept Phase 2a study of RAD1901, an investigational selective estrogen receptor modulator (SERM) undergoing clinical evaluation for treatment of vasomotor symptoms (menopausal hot flashes).

24 Mar 2009

Quality of life may impact coping strategies of young women with breast cancer

Numerous studies have shown a relationship between coping strategies and quality of life (QOL) among women with breast cancer. In a study published today in the online edition of Journal of Behavioral Medicine, an investigation of coping strategies and quality of life among younger women with breast cancer suggests that QOL determines the use of coping strategies.

24 Mar 2009

Bionovo announces publication of positive trial results for Menerba

Bionovo, Inc. has announced the online publication of a peer-reviewed article in the journal, Menopause, reporting Menerba (formerly MF101) is well tolerated, safe and effective for the treatment of vasomotor symptoms (hot flashes and night sweats) associated with menopause.

3 Mar 2009

Guidance for evaluating menopause-like condition in girls and young women

A comprehensive plan to help health care professionals diagnose and treat primary ovarian insufficiency-a menopause-like condition affecting girls and young women that may occur years before normal menopause is expected-has been developed by a scientist at the National Institutes of Health.

5 Feb 2009